

Eric A Klein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11052451/eric-a-klein-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

12,534
citations

48
h-index

111
g-index

120
ext. papers

14,679
ext. citations

6.9
avg, IF

5.56
L-index

#	Paper	IF	Citations
119	Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 39-51	27.4	1518
118	Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1549-56	27.4	1150
117	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016 , 69, 428-35	10.2	762
116	Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2035-41	2.2	694
115	Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 1325-32	27.4	503
114	Predicting 15-year prostate cancer specific mortality after radical prostatectomy. <i>Journal of Urology</i> , 2011 , 185, 869-75	2.5	463
113	Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. <i>PLoS Pathogens</i> , 2006 , 2, e25	7.6	443
112	A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. <i>European Urology</i> , 2014 , 66, 550-60	10.2	421
111	Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4300-5	2.2	351
110	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014 , 46, 1103-9	36.3	331
109	The surgical learning curve for prostate cancer control after radical prostatectomy. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1171-7	9.7	309
108	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020 , 31, 745-759	10.3	303
107	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Journal of the National Cancer Institute</i> , 2005 , 97, 94-102	9.7	275
106	RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. <i>Nature Genetics</i> , 2002 , 32, 581-3	36.3	241
105	Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. <i>BMC Genomics</i> , 2013 , 14, 690	4.5	226
104	Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1132-41	9.7	223
103	Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3376-85	2.2	197

102	Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt456	9.7	184
101	An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 1655-60	11.5	177
100	Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. <i>European Urology</i> , 2007 , 51, 1175-84	10.2	172
99	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 896-905	27.4	171
98	Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. <i>Journal of Urology</i> , 2009 , 182, 1357-63	2.5	150
97	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2015 , 67, 1160-1167	10.2	133
96	A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. <i>European Urology</i> , 2015 , 67, 778-86	10.2	126
95	Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2Ψ5R oligoadenylates. <i>Cancer Research</i> , 2003 , 63, 6795-801	10.1	118
94	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. <i>Urology</i> , 2016 , 90, 148-52	1.6	116
93	Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. <i>Journal of Urology</i> , 2008 , 179, 2212-6; discussion 2216-7	2.5	111
92	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 581-590	2.2	107
91	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. <i>European Urology</i> , 2015 , 68, 555-67	10.2	100
90	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2789-96	2.2	99
89	Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. <i>Cancer Prevention Research</i> , 2011 , 4, 1761-9	3.2	93
88	Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. <i>European Urology</i> , 2008 , 53, 960-6	10.2	85
87	Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. <i>Journal of Virology</i> , 2008 , 82, 9964-77	6.6	85
86	Association of Mycoplasma hominis infection with prostate cancer. <i>Oncotarget</i> , 2011 , 2, 289-97	3.3	81
85	Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1494-504	4	78

84	Risk factors for prostate cancer. <i>Nature Reviews Urology</i> , 2009 , 6, 87-95		77
83	Inflammation, infection, and prostate cancer. <i>Current Opinion in Urology</i> , 2008 , 18, 315-9	2.8	75
82	Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. <i>Journal of Virology</i> , 2009 , 83, 6995-7003	6.6	66
81	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1474-1494	2.2	66
80	Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. <i>Cancer</i> , 2009 , 115, 1005-10	6.4	62
79	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
78	Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. <i>European Urology</i> , 2014 , 65, 675-80	10.2	61
77	The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. <i>European Urology</i> , 2010 , 58, 90-5	10.2	58
76	Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Cancer Prevention Research</i> , 2014 , 7, 886-95	3.2	52
75	The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. <i>Nature Reviews Urology</i> , 2010 , 7, 392-402	5.5	51
74	Chemoprevention of prostate cancer. <i>Journal of Urology</i> , 2009 , 182, 499-507; discussion 508	2.5	51
73	Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. <i>Urology</i> , 2010 , 76, 1251-7	1.6	49
72	Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. <i>Journal of Urology</i> , 2008 , 180, 150-4; discussion 154	2.5	48
71	Variations among experienced surgeons in cancer control after open radical prostatectomy. <i>Journal of Urology</i> , 2010 , 183, 977-82	2.5	47
70	Leveraging population admixture to characterize the heritability of complex traits. <i>Nature Genetics</i> , 2014 , 46, 1356-62	36.3	45
69	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1549-1557	4	41
68	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1050-1058	10.58	39
67	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	38

66	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017 , 8, 18949-18967	3.3	38
65	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016 , 7, 10979	17.4	37
64	Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. <i>European Urology</i> , 2014 , 66, 204-10	10.2	37
63	Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. <i>Journal of Virology</i> , 2011 , 85, 4547-57	6.6	37
62	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12021-12021	2.2	37
61	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. <i>Human Molecular Genetics</i> , 2015 , 24, 5603-18	5.6	35
60	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018 , 73, 524-532	10.2	35
59	Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. <i>Urology</i> , 2005 , 66, 881	1.6	35
58	Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. <i>European Urology</i> , 2015 , 67, 204-9	10.2	34
57	Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. <i>Journal of Urology</i> , 2012 , 187, 2005-10	2.5	33
56	In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. <i>PLoS ONE</i> , 2012 , 7, e44954	3.7	33
55	Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. <i>Retrovirology</i> , 2010 , 7, 68	3.6	33
54	Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. <i>JAMA Ophthalmology</i> , 2015 , 133, 17-24	3.9	30
53	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017 , 197, 122-128	2.5	29
52	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017 , 8, 50804-50813	3.3	27
51	Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. <i>Cell Reports</i> , 2015 , 13, 2135-46	10.6	26
50	Fellowship training as a modifier of the surgical learning curve. <i>Academic Medicine</i> , 2010 , 85, 863-8	3.9	25
49	Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. <i>Journal of Urology</i> , 2017 , 198, 591-599	2.5	22

48	A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Cancer Prevention Research</i> , 2014 , 7, 950-7	3.2	21
47	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019 , 125, 391-397	6.4	20
46	Applying precision medicine to the active surveillance of prostate cancer. <i>Cancer</i> , 2015 , 121, 3403-11	6.4	18
45	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , 2021 , 27, 4221-4229	12.9	18
44	Chemoprevention of prostate cancer: an updated view. <i>World Journal of Urology</i> , 2012 , 30, 189-94	4	17
43	Moving a randomized clinical trial into an observational cohort. <i>Clinical Trials</i> , 2013 , 10, 131-42	2.2	17
42	Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. <i>Urology</i> , 2011 , 77, 946-50	1.6	16
41	Selenium and vitamin E: interesting biology and dashed hope. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 283-5	9.7	16
40	Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. <i>European Urology</i> , 2009 , 55, 412-19	10.2	16
39	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 136-143	6.2	16
38	Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. <i>Journal of Urology</i> , 2008 , 179, 1344-8	2.5	14
37	Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. <i>Oncotarget</i> , 2016 , 7, 33855-65	3.3	14
36	Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1. <i>PLoS ONE</i> , 2012 , 7, e36072	3.7	13
35	Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?. <i>Journal of Urology</i> , 2014 , 192, 1094-9	2.5	12
34	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3049-3049	2.2	12
33	Chemoprevention of prostate cancer. <i>Urologic Clinics of North America</i> , 2010 , 37, 11-21, Table of Contents	9	11
32	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021 , 13,	6.6	11
31	Surgical management of high-risk, localized prostate cancer. <i>Nature Reviews Urology</i> , 2020 , 17, 679-690	5.5	9

30	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. <i>Journal of Urology</i> , 2018 , 199, 438-444	2.5	8
29	No biological evidence of XMRV in blood or prostatic fluid from prostate cancer patients. <i>PLoS ONE</i> , 2012 , 7, e36073	3.7	8
28	Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. <i>Urology</i> , 2017 , 107, 184-189	1.6	6
27	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. <i>Eur urol</i> 2014;66:550-60. <i>European Urology</i> , 2014 , 66, e117-8	10.2	6
26	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. <i>BJU International</i> , 2017 , 119, 961-967	5.6	5
25	Prostate cancer: MR-TRUS fusion biopsy--defining a new standard. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 253-4	19.4	5
24	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. <i>Urology</i> , 2018 , 121, 132-138	1.6	5
23	In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins. <i>Virology</i> , 2011 , 421, 28-33	3.6	5
22	Sexual Transmission of XMRV: A Potential Infection Route. <i>Advances in Virology</i> , 2011 , 2011, 965689	1.9	5
21	Epidemiology, Etiology, and Prevention of Prostate Cancer 2012 , 2704-2725.e7		5
20	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	5
19	Molecular markers in urologic oncology: prostate cancer. <i>Current Opinion in Urology</i> , 2016 , 26, 225-30	2.8	5
18	Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. <i>International Journal of Cancer</i> , 2011 , 128, 1697-702	7.5	4
17	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5574-5574	2.2	4
16	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. <i>Cancer Epidemiology</i> , 2018 , 55, 117-122	2.8	3
15	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019 , 125, 3853-3863	6.4	3
14	XMRV Discovery and Prostate Cancer-Related Research. <i>Advances in Virology</i> , 2011 , 2011, 432837	1.9	3
13	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. <i>Nature Reviews Urology</i> , 2017 , 14, 59-64	5.5	2

12	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 459.e15-459.e24	2.8	2
11	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. <i>Urology</i> , 2019 , 130, 106-112	1.6	2
10	The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> 2021, 11, 2171. <i>Diagnostics</i> , 2022 , 12, 1243	3.8	2
9	Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. <i>Trials</i> , 2016 , 17, 400	2.8	1
8	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
7	Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 40, 104.e1-104.e1	2.8	0
6	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.. <i>JCO Precision Oncology</i> , 2020 , 4, 1228-1238	3.6	0
5	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. <i>Journal of Translational Genetics and Genomics</i> , 2021 , 5, 50-61	1.7	0
4	Prostate cancer prevention 2018 , 145-170		
3	Multicancer early detection.. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022 ,	5.9	
2	Tissue-Based Markers for Risk Prediction. <i>Current Clinical Urology</i> , 2018 , 121-133		
1	Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy 2013 , 17-36		